Still, extracorporeal treatments rapidly reduce excessive concentrations of 25-OH-vitamin D3, which have been shown to directly activate the vitamin D receptor, thereby maintaining hypercalcemia [7]. The gene discussed is VDR; the disease is hypercalcemia disease.